This proposal will attempt to identify expression-based markers for breast cancer and develop assays using these markers to detect circulating breast cancer cells. Our application has been developed as a collaborative effort between the Duke Breast Cancer Program and Abbott Diagnostic Breast Cancer Venture Group and will utilize the considerable strengths of each institution. The basic approach for marker identification takes advantage of ongoing (and separately funded) efforts using powerful new genomics tools. At Duke, SAGE (serial analysis of gene expression) libraries of breast cancer and normal breast epithelium are being constructed as part of CGAP. Also at Duke, a series of 20 primary breast cancers will be analyzed using high-density Affymetrix expression chips (30,000 genes/ESTs will be sampled). Finally, at Abbott Diagnostics, markers have already been identified by using the Incyte Corporation expression libraries. These three sources of expression data will be compared electronically and the most promising markers that are expressed at high levels in a tissue or cancer specific manner will be identified. After the in silico analysis, the lead markers will be put through a validation algorithm that will include northern blotting, multiple tissue RNA dot blots, RT-PCR, and in situ cytohybridization. A panel of breast cell lines and a series of 50 primary breast cancers will be used to determine how commonly expressed these markers are in the target tissue. After these initial validation steps, a series of reconstitution experiments will be performed by spiking normal whole blood with known numbers of breast cancer cells, derived from cell lines and malignant effusions. Epithelial cells will be purified using magnetic bead/antibody technology and the resulting purified samples will be analyzed by flow cytometry, histology, and quantitative RT-PCR. Towards increasing sensitivity, a separate and parallel screen will focus on markers that are highly overexpressed in a subset of breast cancers. PCR multiplexing approaches will be explored in this context and will also include using telomerase gene (TERT) expression as a cancer specific marker in conjunction with other lead markers. Antibodies to the most promising candidates will be developed, particularly for gene products that may be secreted or presented on the cell surface. Finally, a collection of whole blood and serum samples will be obtained from women newly diagnosed with breast cancer at Duke. This bank will constitute a primary validation set for markers and approaches that have proven to be the most robust.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA084955-02
Application #
6175287
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (O1))
Program Officer
Srivastava, Sudhir
Project Start
1999-09-30
Project End
2004-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
2
Fiscal Year
2000
Total Cost
$401,115
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Adams, Daniel L; Adams, Diane K; Alpaugh, R Katherine et al. (2016) Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiol Biomarkers Prev 25:1037-42
Piccolo, Stephen R; Hoffman, Laura M; Conner, Thomas et al. (2016) Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol 12:860
Ryser, Marc D; Worni, Mathias; Turner, Elizabeth L et al. (2016) Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. J Natl Cancer Inst 108:
Marks, Jeffrey R; Anderson, Karen S; Engstrom, Paul et al. (2015) Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiol Biomarkers Prev 24:435-41
Elsarraj, Hanan S; Hong, Yan; Valdez, Kelli E et al. (2015) Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Breast Cancer Res 17:128
Tang, Xiaohu; Lin, Chao-Chieh; Spasojevic, Ivan et al. (2014) A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res 16:415
Wolf, Omer; Weissman, Oren; Harats, Moti et al. (2013) Birth wind and fire: raising awareness to operating room fires during delivery. J Matern Fetal Neonatal Med 26:1303-5
Schildkraut, Joellen M; Iversen, Edwin S; Akushevich, Lucy et al. (2013) Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev 22:1709-21
Marks, Jeffrey R (2013) Refining the role of BRCA1 in combating oxidative stress. Breast Cancer Res 15:320
Sfakianos, Gregory P; Iversen, Edwin S; Whitaker, Regina et al. (2013) Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol Oncol 129:159-64

Showing the most recent 10 out of 33 publications